Monya Ewaida

Quality Assurance Engineer at Protalix Biotherapeutics - Miami, FL, US

Monya Ewaida's Colleagues at Protalix Biotherapeutics
Eyal Rubin

SVP, Chief Financial Officer

Contact Eyal Rubin

David Meraro

Senior director of quality control

Contact David Meraro

Dana Lapid

Clinical Regulatory Affairs specialist

Contact Dana Lapid

Shlomzion Shen

Director of Business Development

Contact Shlomzion Shen

Irina Weyzman

QA Systems and Laboratories Department Manager

Contact Irina Weyzman

Michal Leibovitz

Computerized Systems Validation Engineer

Contact Michal Leibovitz

Peter Vit

QP - Chief Pharmacist

Contact Peter Vit

View All Monya Ewaida's Colleagues
Monya Ewaida's Contact Details
HQ
305-371-4112
Location
Israel
Company
Protalix Biotherapeutics
Monya Ewaida's Company Details
Protalix Biotherapeutics logo, Protalix Biotherapeutics contact details

Protalix Biotherapeutics

Miami, FL, US • 250 - 499 Employees
BioTech/Drugs

Protalix (NYSE, TASE: PLX) is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®. Protalix was the first company to gain FDA approval of a protein produced through plant cell-based in suspension expression system. Protalix's unique expression system represents a new method for developing recombinant proteins in an industrial-scale manner.Protalix's first product manufactured by ProCellEx, taliglucerase alfa, was approved for marketing by the FDA in May 2012 and, subsequently, by the regulatory authorities of other countries. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights for taliglucerase alfa, excluding Brazil, where Protalix retains full rights.Protalix's development pipeline consists of proprietary versions of recombinant therapeutic proteins that target established pharmaceutical markets, including the following product candidates: pegunigalsidase alfa, a modified version of the recombinant human α–Galactosidase–A protein for the proposed treatment of Fabry disease; OPRX–106, an orally-delivered anti-inflammatory treatment; alidornase alfa for the treatment of Cystic Fibrosis; and others. Protalix has partnered with Chiesi Global Rare Diseases, both in the United States and outside the United States, for the development and commercialization of pegunigalsidase alfa.

B2B Biotechnology Cleantech Food & Beverages Healthcare Pharmaceuticals Solar Power Wind Power BioTech/Drugs Commercial Physical Research
Details about Protalix Biotherapeutics
Frequently Asked Questions about Monya Ewaida
Monya Ewaida currently works for Protalix Biotherapeutics.
Monya Ewaida's role at Protalix Biotherapeutics is Quality Assurance Engineer.
Monya Ewaida's email address is ***@protalix.com. To view Monya Ewaida's full email address, please signup to ConnectPlex.
Monya Ewaida works in the Research industry.
Monya Ewaida's colleagues at Protalix Biotherapeutics are Eyal Rubin, David Meraro, Dana Lapid, Shlomzion Shen, Irina Weyzman, Michal Leibovitz, Peter Vit and others.
Monya Ewaida's phone number is 305-371-4112
See more information about Monya Ewaida